Financial Consulate’s Ionis Pharmaceuticals IONS Stock Holding History

Financial Consulate’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$447	Buy	+10	New	+$568	﹤0.01%	1491

Other funds holding IONS

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Nicollet Investment Management Minneapolis, Minnesota $336M AUM 22.24% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Financial Consulate's IONS Position: Q3 2026 in Review

Financial Consulate opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2026: 10 shares worth $447. The stake represents ﹤0.01% of the portfolio and ranks #1491 among its holdings.

60 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

Financial Consulate held 10 shares of Ionis Pharmaceuticals worth $447 as of Q3 2026.
Ionis Pharmaceuticals was a new Financial Consulate position in Q3 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1491 holding.
60 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.